Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,693
Total Claims
$4.9M
Drug Cost
1,003
Beneficiaries
$4,836
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+243%
Cost per patient vs peers
$4,836 vs $1,411 avg
+470%
Brand preference vs peers
60.6% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
Brand vs Generic
Brand: 6,907 claims · $4.7M
Generic: 4,488 claims · $99K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 861 | $852K |
| Empagliflozin | 685 | $649K |
| Semaglutide | 593 | $586K |
| Dapagliflozin Propanediol | 530 | $470K |
| Sitagliptin Phosphate | 334 | $296K |
| Sitagliptin Phos/Metformin Hcl | 263 | $264K |
| Insulin Glargine,hum.Rec.Anlog | 492 | $238K |
| Insulin Lispro | 312 | $203K |
| Levothyroxine Sodium | 1,482 | $143K |
| Tirzepatide | 134 | $142K |
| Empagliflozin/Metformin Hcl | 125 | $118K |
| Dapaglifloz Propaned/Metformin | 126 | $113K |
| Empaglifloz/Linaglip/Metformin | 68 | $83K |
| Linagliptin | 99 | $75K |
| Sitagliptin Phos/Metformin Hcl | 52 | $63K |
Prescribing Profile
Patient Profile
71
Avg Age
64%
Female
1.86
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data